Borna disease virus and human disease.
The biology of Borna disease virus (BDV) strongly supports the likelihood of human infection with BDV or a variant of BDV. Thus far, the evidence supporting BDV infection in humans has initiated much controversy among basic and clinical scientists; only time and additional research will support or refute the hypothesis of human BDV infection. Until an assay of acceptable specificity and sensitivity has been developed, validated, and used to document human BDV infection, scientists cannot reasonably begin to associate BDV infection with specific disease syndromes. Clinical studies seeking causal associations between BDV infection and specific diseases must ensure the proper identification of the BDV infection status of patients and control subjects by using a validated, highly sensitive, and highly specific assay (or series of assays). For clinical studies, a highly sensitive "screening" test followed by a highly specific confirmatory test will be of significant benefit. Although it is possible to formulate hypotheses about the clinical outcomes of human BDV infection based on animal model work, to date no human disease has been causally linked to human BDV infection. Scientists all over the world are actively pursuing these issues, and with continuing advances in clinical and basic BDV research, the answers cannot be far away.
Carbone
K M
KM
FDA/CBER, HFM 460, 8800 Rockville Pike, Bethesda, MD 20892, USA. Carbonek@cber.fda.gov
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001890:Borna Disease / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000821:virology; D001891:Borna disease virus / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity*; D006801:Humans; D001523:Mental Disorders / Q000209:etiology
D000914:Antibodies, Viral